Background: Factor (F)XII triggers contact activation by binding to foreign surfaces, with the epidermal growth factor-like 1 (EGF-1) domain being the primary binding site. Blocking FXII surface-binding might hold therapeutic value to prevent medical device-induced thrombosis.
Objectives: To unravel and prevent EGF-1-mediated FXII surface-binding with a variable domain of heavy chain-only antibody (VH).
Purpose Of Review: Von Willebrand factor (VWF) plays a pivotal role in primary hemostasis. A Disintegrin And Metalloproteinase with a ThromboSpondin type 1 motif, member 13 (ADAMTS13) is primarily responsible for cleaving ultra-large VWF multimers into smaller, less adhesive forms. However, plasmin has also been shown to cleave VWF multimers.
View Article and Find Full Text PDFNeurodegener Dis Manag
December 2023
Parkinson's disease (PD) is a neurodegenerative disorder with significant genetic influence. The gene is a major genetic contributor, particularly the Gly2019Ser mutation. This focused review investigates the global distribution of mutations, with emphasis on Gly2019Ser and other pathogenic variants.
View Article and Find Full Text PDF